TITLE:
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

CONDITION:
Schizophrenia

INTERVENTION:
Intramuscular Olanzapine Depot

SUMMARY:

      Key objectives of this clinical study are to:

        -  Determine how well intramuscular (IM) olanzapine depot works compared to placebo

        -  Evaluate the safety and tolerability of IM olanzapine depot compared to placebo

        -  Evaluate different doses of IM olanzapine depot compared to placebo to identify the
           best dose(s).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Patients must have schizophrenia and be experiencing a psychotic episode

          -  Each patient must have a level of understanding sufficient to complete all tests and
             examinations required by the protocol, and to provide informed consent

          -  Patient must not have participated in a clinical trial of another investigational
             drug, including olanzapine, within 1 month (30 days) prior to the study entry

          -  Female patients must not be pregnant or breast-feeding

          -  Female patients must not be experiencing acute, serious or unstable medical
             conditions other than schizophrenia

        Exclusion Criteria:

          -  Patients who were previously treated with olanzapine and are considered to be
             treatment-resistant to olanzapine, in the opinion of the investigator

          -  One or more seizures without a clear and resolved etiology is exclusionary. However,
             if the patient has had one or more seizures in the past with an identifiable
             etiology, and that etiology has been resolved, the patient may be entered.

          -  Treatment with clozapine within 4 weeks prior to visit 1

          -  DSM-IV or DSM-IV-TR substance (except nicotine and caffeine) dependence within the
             past 30 days

          -  Treatment with remoxipride within 6 months (180 days) prior to visit 1
      
